Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00062374 · ClinicalTrials.gov registry record · Phase 2
Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction
A Phase 2 study of Gastric Adenocarcinoma and Stage IV Gastric Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT00062374 is a Phase 2 study of Gastric Adenocarcinoma and Stage IV Gastric Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 55 participants, below the 244-participant average among 47 other Gastric Adenocarcinoma trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00062374, a Phase 2 study of Gastric Adenocarcinoma and Stage IV Gastric Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial is studying how well giving irinotecan together with cisplatin works in treating patients who are undergoing surgical resection for locally advanced cancer of the stomach or gastroesophageal junction. Drugs used in chemotherapy, such as irinotecan and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug and giving them before surgery may shrink the tumor so that it can be removed during surgery.
Conditions Studied
Interventions
- PROCEDURE Computed Tomography
- DRUG Cisplatin
- DRUG Irinotecan Hydrochloride
- RADIATION Fludeoxyglucose F-18
- OTHER Fluorothymidine F-18
Study Locations (1)
New York
- Memorial Sloan-Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2003-06 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00062374
The ClinicalTrials.gov registry entry for NCT00062374 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 244-participant average among 47 other Gastric Adenocarcinoma trials with a reported enrollment target (77% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Gastric Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Computed Tomography is the first listed.
NCT00062374 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00062374 about?
NCT00062374 is a clinical study titled "Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction". This phase II trial is studying how well giving irinotecan together with cisplatin works in treating patients who are undergoing surgical resection for locally advanced cancer of the stomach or gastroesophageal junction. Drugs used in chemotherapy, such as irinotecan and cisplatin, work in different...
What is the current status of trial NCT00062374?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2003-06. Estimated completion is 2011-06.
What conditions does trial NCT00062374 study?
This clinical trial studies the following conditions: Gastric Adenocarcinoma, Stage IV Gastric Cancer, Stage III Gastric Cancer, Stage II Gastric Cancer.
What interventions are being tested in trial NCT00062374?
The interventions under investigation include: Computed Tomography (PROCEDURE), Cisplatin (DRUG), Irinotecan Hydrochloride (DRUG), Fludeoxyglucose F-18 (RADIATION), Fluorothymidine F-18 (OTHER).
Who is sponsoring clinical trial NCT00062374?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00062374 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study
RECRUITING · Phase 2
-
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
RECRUITING · Phase 2
-
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
RECRUITING · Phase 2
-
A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
RECRUITING · Phase 2
-
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.